Abstract: The present disclosure provides systems and methods for radio-luminescent imaging dosimetry of variable dose rate radiation beams at high spatial resolution. Exemplary embodiments include time-gating one or more camera shutters such that one image frame from a plastic scintillator detector (PSD) is captured per camera shutter for each radiation beam pulse produced from a pulsed beam accelerator directed toward the PSD.

Abstract: System and methods for forming a micropillar array for an evaporative heat exchanger include selecting a preliminary shape for a micropillar, determining a droplet shape that is generated by the preliminary shape, and generating at least one curve that defines the droplet shape. The system and methods also include performing an evaporative simulation based on the curve and selecting a final micropillar shape based on the evaporative simulation. The system and methods further include fabricating an array of micropillars including at least one micropillar having the final micropillar shape.

Abstract: Among the various aspects of the present disclosure is the provision of methods for detecting cancer in Neurofibromatosis Type 1 (NF1) patients.

Abstract: Compositions and methods of treating a thrombotic disease, disorder, or condition in a subject in need thereof are provided. Exemplary compositions comprise at least one ERO1? inhibitor. Exemplary methods comprise administering to the subject at least one ERO1? inhibitor. Methods of inhibiting ERO1? in a subject having a thrombotic disease, and methods of reducing platelet thrombus formation in subject having a thrombotic disease, are also provided.

Abstract: The present disclosure is generally directed to quinolinyl and pyridinyl containing compounds targeting on alpha-synuclein for neurological diseases. These compounds, particularly radiolabeled versions of these compounds, can be particularly useful in PET scans targeting diseases such as Parkinson's disease (PD), Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA).

Abstract: Methods and systems for (i) modulating, enhancing, or maintaining slow waves using phase-locked neurostimulation; (ii) modulating, enhancing, or maintaining unconsciousness using phase-locked neurostimulation; and (iii) reducing the amount of anesthesia required in a subject using phase-locked neurostimulation are provided. The present disclosure is directed to applying neurostimulation to the brain of a subject to enhance anesthesia, thereby decreasing drug requirements of anesthesia.

Abstract: Methods for generating blastoids from naïve hPSCs are provided. Exemplary methods include exposing the naïve hPSCs to 5i/L/A, aggregating the exposed hPSCs in N2B27, and treating the aggregated hPSCs with a simplified blastocyst induction medium (“BIM”). Also provided are systems for extended culture of human blastoids on a 3D matrix, including blastoids generated from naïve hPSCs according to methods described herein.

Abstract: Disclosed herein is a method for deforming patient images obtained with a couch of one set of physical properties (e.g. curvature) based on the physical properties (e.g. curvature) of a couch where radiation therapy treatment will be performed. Also disclosed herein is a radiotherapy delivery system which includes a non-flat couch top, on-couch planning, and optional deformable image registration. The methods and systems use images from scanners of various couch top shapes for treatment of radiotherapy patients without a need for specialized treatment planning imaging. In such methods and systems, treatment delivery can be performed based on only diagnostic images and setup images acquired at the time of treatment on the treatment machine. The radiotherapy delivery systems can include any combination of volumetric imaging with radiotherapy treatments with photon, proton, electron, and\or other particle radiation.

Abstract: The present disclosure provides method of treating or preventing a microbial infection caused by a prokaryotic pathogen in a subject, the method comprising administering a compound of Formula (I) as set forth in the specification. In one embodiment, the prokaryotic pathogen belongs to the genus Staphylococcus.

Abstract: Systems and methods for microscopic imaging include an inverted microscope directed at a sample on a coverglass, where the sample is comprised of one or more cells and one or more chromophores. A ridge separates the coverglass from a silicon dioxide layer, and a silicon mirror is situated on the silicon dioxide layer, opposite the ridge and coverglass, while a weight is situated against the silicon mirror, opposite the silicon dioxide layer. The inverted microscope uses a spatial light modulator to diffract light through a linear polarizer and a filter wheel comprised of one or more Fourier filters. A beam or beams of s-polarized light is directed to the silicon mirror to create axial light modulation with its reflection on the silicon mirror, producing image data that is captured at a light detector.

Abstract: The present disclosure provides compounds represented by Formula I: and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof, wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.

Abstract: Systems, devices, and methods for system for monitoring uterine contractions non-invasively using surface electrode measurements are described herein.

Abstract: Disclosed herein is a method for predicting a patient response to a sodium ion channel blocker such as mexiletine when the patient has LQT syndrome or an arrhythmia. The method generally comprises determining a plurality of parameters associated with sodium ion channels; generating a model for patient response by using a partial least squared (PLS) regression analysis on said plurality of parameters; and using the model to predict the patient response if the patient is administered a sodium ion channel blocker such as mexiletine.

Abstract: Disclosed herein is a redox flow battery (RFB). The battery generally includes: a positive electrolyte that is a first metal ion, a negative electrolyte that is a second metal ion, an ion exchange membrane positioned between the positive electrolyte and the negative electrolyte. The membrane is configured to restrict and/or prevent the passage of the first metal ion and/or the second metal ion therethrough, and is configured to maintain ionic conductivity between the positive electrolyte and the negative electrolyte.

Abstract: A three-dimensional electrospun biomedical patch includes a first polymeric scaffold having a first structure of deposited electrospun fibers extending in a plurality of directions in three dimensions to facilitate cellular migration for a first period of time upon application of the biomedical patch to a tissue, wherein the first period of time is less than twelve months, and a second polymeric scaffold having a second structure of deposited electrospun fibers. The second structure of deposited electrospun fibers includes the plurality of deposited electrospun fibers configured to provide structural reinforcement for a second period of time upon application of the three-dimensional electrospun biomedical patch to the tissue wherein the second period of time is less than twelve months. The three-dimensional electrospun biomedical patch is sufficiently pliable and resistant to tearing to enable movement of the three-dimensional electrospun biomedical patch with the tissue.

Abstract: The invention includes methods and compositions for the treatment and prevention of a disease or condition resulting from dysregulation of USB1 and resulting expression of downstream miRNAs. In one preferred embodiment, the invention may include inhibiting the expression or activity of USB1 resulting in the downregulation of downstream miRNA expression. In alternative embodiments, the invention includes methods and compositions for the treatment and prevention of a disease or condition resulting from dysregulation of miRNAs downstream of USB1, namely through the inhibition of PAPD5 and/or PAPD7, resulting in the upregulation of said downstream miRNA expression.

Abstract: Among the various aspects of the present disclosure is the provision of an electrophoresis and electroporation device, system, and methods of use thereof. Devices to administer drugs with electrophoresis and electroporation are described. Systems to administer drugs with an electrophoresis and electroporation device by applying voltages with a power source and controller are also described. Also disclosed are methods of administering a therapeutic agent with an electrophoresis and electroporation device or system.

Abstract: Among the various aspects of the present disclosure is the provision of a regulator of tumor cell functions and uses thereof. Methods to treat a cancer patient with immunotherapy and a Zbtb46 modulation agent are disclosed. A method to identify a cancer patient in need of an adjuvant therapy to an immunotherapy is also disclosed.

Abstract: The present invention discloses a unique panel of gene transcripts down-regulated in patients with coronary artery disease (CAD). Methods and compositions for detecting CAD in patient blood samples are provided.

Abstract: The present disclosure provides a composition comprising a panel of probes for detecting one or more viruses in a sample. The panel of probes may be used to detect viruses in a biological sample obtained from a subject.